Status:
UNKNOWN
Immune Checkpoints in Colorectal Cancer
Lead Sponsor:
Chinese University of Hong Kong
Conditions:
Colorectal Cancer
Eligibility:
All Genders
18-80 years
Brief Summary
Colorectal cancer (CRC) ranked the first in cancer incidence in Hong Kong and it is frequently lethal with heterogeneous drug responses and survival outcomes. Immune-based approaches targeting to enha...
Detailed Description
Aim: To examine the role of PD-L1/PD1 in immune cell-mediated cytotoxicity in colorectal cancer patients. Objectives: 1. Comprehensive investigation of PD-L1/PD1 in colorectal cancer in association w...
Eligibility Criteria
Inclusion
- colorectal cancer patients undergoing resection or endoscopic examination at the Department of Surgery, Prince of Wales Hospital, Shatin, Hong Kong
Exclusion
- patients who do not consent
Key Trial Info
Start Date :
May 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
May 1 2024
Estimated Enrollment :
68 Patients enrolled
Trial Details
Trial ID
NCT04051450
Start Date
May 1 2020
End Date
May 1 2024
Last Update
February 5 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Chinese University of Hong Kong
Hong Kong, Hong Kong